A preliminary report of head-to-head comparison of 18-gene-based clinical-genomic model and oncotype DX 21-gene assay for predicting recurrence of early-stage breast cancer
Journal
Japanese journal of clinical oncology
Journal Volume
49
Journal Issue
11
Date Issued
2019-12-18
Author(s)
Yang, Po-Sheng
Lee, Yi-Hsuan
Chung, Chi-Feng
Chang, Yuan-Ching
Wang, Ming-Yang
Shih, Kuan-Hui
Lei, Jason
Yu, Ben-Long
Cheng, Skye H
Abstract
Background: The information of Oncotype DX applied in Asian breast cancer patients is limited. A recurrence index for distant recurrence (RI-DR) has been developed for early-stage breast cancer (EBC) from tumor samples in Chinese patients. In this study, we compared the prognostic performance of the Oncotype DX (ODx) recurrence score (RS) with the RI-DR for any recurrence risk type.
Materials and methods: One hundred thirty-eight (138) patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative EBC who were previously tested with ODx were included for testing with the RI-DR. The cutoff score to partition the low- and high-risk patients was 26 for RS and 36 for RI-DR. The primary endpoint was recurrence-free survival (RFS).
Results: The concordance between the RI-DR and RS was 83% in N0 patients and 81% in node-positive patients when the RS score cutoff was set at 26. With a median follow-up interval of 36.8 months, the 4-year RFS for the high- and low-risk groups categorized by the RS were 61.9% and 95.0%, respectively (hazard ratio: 10.6, 95.0% confidence interval [CI]: 1.8-62.9). The 4-year RFS in the high- and low-risk groups categorized by the RI-DR were 72.6% and 98.5%, respectively (hazard ratio: 18.9, 95% CI: 1.8-138.8).
Conclusion: This paper illustrated the performance of RI-DR and ODx RS in breast cancer women in Taiwan. There was high concordance between the RI-DR and RS. The RI-DR is not inferior to the RS in predicting RFS in EBC patients. This study will fill the gap between the current and best practice in Chinese patients.
Subjects
NanoString
breast cancer
distant recurrence
gene-expression profiling
prognosis
SDGs
Other Subjects
adult; aged; Article; BLM gene; BUB1B gene; C16ORF7 gene; cancer patient; cancer prognosis; cancer recurrence; cancer staging; CCNB1 gene; CCR1 gene; cohort analysis; confidence interval; controlled study; DDX39 gene; diagnostic test accuracy study; DTX2 gene; early cancer; ENSA gene; estrogen receptor positive breast cancer; female; follow up; hazard ratio; high risk patient; human; human epidermal growth factor receptor 2 negative breast cancer; human tissue; intermethod comparison; low risk patient; major clinical study; middle aged; MMP15 gene; NFATC2IP gene; OBSL1 gene; oncogene; oncological parameters; PIM1 gene; prediction; predictive value; progesterone receptor positive breast cancer; PTI1 gene; RCHY1 gene; recurrence index for distant recurrence; recurrence risk; recurrence score; sensitivity and specificity; STIL gene; Taiwan; TCF3 gene; TPX2 gene; TRPV6 gene
Publisher
Oxford University Press
Type
journal article